Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/285274 
Year of Publication: 
2022
Citation: 
[Journal:] Health Economics Review [ISSN:] 2191-1991 [Volume:] 12 [Issue:] 1 [Article No.:] 37 [Year:] 2022 [Pages:] 1-12
Publisher: 
Springer, Heidelberg
Abstract: 
Background: Well-functioning competitive markets are key to controlling generic drug prices. This is important since over 90% of all drugs sold in the US are generics. Recently, there have been examples of large price increases in the generic market. Methods: This paper examines price trajectories for generic drugs using a group-based trajectory modelling approach (GBTM). We fit the model using quarterly price information in the IBM MarketScan claims database for the past decade. Results: We identify three dominant price trajectories for this period: rapid increase trajectories, slow decline and rapid decline. Most generic drugs show a slow or a rapid decline in price trajectories. However, around 17% of all generic drugs show rapid price increase trajectories. Conclusions: As Congress is exploring an excise tax on drugs whose list price increases faster than the rate of inflation, we discuss what drugs would be most likely to be affected by this law.
Subjects: 
Drug
Generic drugs
Group based trajectory models
Mergers and acquisitions
Prices
Persistent Identifier of the first edition: 
Creative Commons License: 
cc-by Logo
Document Type: 
Article

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.